Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
A phase III trial in The Lancet found the addition of rilotumumab (an antibody that targets the hepatocyte growth factor) to chemotherapy did not improve patient outcomes.
Read Source
